...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine >Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
【24h】

Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma

机译：抗血管生成和免疫疗法：创立肾细胞癌的定制方法的新型矛盾

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Although decision making strategy based on clinico-histopathological criteria is well established, renal cell carcinoma (RCC) represents a spectrum of biological ecosystems characterized by distinct genetic and molecular alterations, diverse clinical courses and potential specific therapeutic vulnerabilities. Given the plethora of drugs available, the subtype-tailored treatment to RCC subtype holds the potential to improve patient outcome, shrinking treatment-related morbidity and cost. The emerging knowledge of the molecular taxonomy of RCC is evolving, whilst the antiangiogenic and immunotherapy landscape maintains and reinforces their potential. Although several prognostic factors of survival in patients with RCC have been described, no reliable predictive biomarkers of treatment individual sensitivity or resistance have been identified. In this review, we summarize the available evidence able to prompt more precise and individualized patient selection in well-designed clinical trials, covering the unmet need of medical choices in the era of next-generation anti-angiogenesis and immunotherapy.
机译：尽管基于临床组织病理学标准的决策策略已经成立，但肾细胞癌（RCC）代表了一种生物生态系统的光谱，其特征在于不同的遗传和分子改变，不同的临床课程和潜在的特定治疗漏洞。鉴于可用的血清药物，对RCC亚型的亚型定制治疗占改善患者结果，萎缩的治疗相关的发病率和成本潜力。 RCC分子分类的新兴了解正在进行，而抗血管生成和免疫治疗景观保持并加强其潜力。虽然已经描述了RCC患者的几种预后因素，但没有确定治疗的可靠预测生物标志物个体敏感性或抗性。在这篇综述中，我们总结了能够在设计精心设计的临床试验中促进更精确和个性化患者选择的可用证据，涵盖下一代抗血管生成和免疫疗法时代的医疗选择的未满足需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号